Research library
Growth Hormone AxisPlausible but unproven in humans
GHRH(1-29)
Sermorelin, GHRH(1-29) fragment
The GHRH(1-29) fragment, the shortest fully active GHRH sequence, used to stimulate physiologic, pulsatile growth hormone secretion.
GHRH(1-29)
~12 min
503A compounded
How Sermorelin works
The shortest fully active piece of GHRH, it tells the pituitary to release growth hormone in natural, physiologic pulses.
Sermorelin
GHRH receptor
Pulsatile GH
↑ IGF-1
Research applications
GH stimulation
Pediatric GHD / diagnostic
Adult GH optimization
Anti aging (off label)
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Molecular profile
Evidence, safety & status
Claimed benefits & evidence
Originally a pediatric GH deficiency therapy and diagnostic, now prescribed off label for adult 'anti aging'/GH optimization. Human efficacy for anti aging endpoints is not established.
Safety & dangers
Injection site reactions, flushing, headache; IGF-1 mediated theoretical risks.
Regulatory status
Was FDA approved as Geref (discontinued 2008 for commercial reasons; approval withdrawn 2009, NOT for safety/efficacy, which legally enables compounding). Available only via 503A/503B compounding by prescription. WADA prohibited (S2, named GHRH analog).
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.
For research use only
For Research Use Only. Not for human or animal consumption. Products are sold strictly for in vitro laboratory research, not for compounding or therapeutic application.